Cardiovascular risk associated with high sodium-containing drugs: A systematic review.
<h4>Background</h4>Excess dietary sodium is associated with increased blood pressure (BP). Some drugs are associated with high sodium intake (in particular effervescent tablets), but the cardiovascular risk associated with such high sodium-containing drugs (HSCD) is largely underevaluate...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0180634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169763855073280 |
|---|---|
| author | Germain Perrin Virginie Korb-Savoldelli Alexandre Karras Nicolas Danchin Pierre Durieux Brigitte Sabatier |
| author_facet | Germain Perrin Virginie Korb-Savoldelli Alexandre Karras Nicolas Danchin Pierre Durieux Brigitte Sabatier |
| author_sort | Germain Perrin |
| collection | DOAJ |
| description | <h4>Background</h4>Excess dietary sodium is associated with increased blood pressure (BP). Some drugs are associated with high sodium intake (in particular effervescent tablets), but the cardiovascular risk associated with such high sodium-containing drugs (HSCD) is largely underevaluated.<h4>Objectives</h4>To summarize the evidence for a potential cardiovascular risk associated with exposure to HSCD, and to highlight possible risk factors associated with this iatrogenic issue; in general and/or specific populations.<h4>Methods</h4>We conducted a systematic review, by searching electronic databases including MEDLINE, EMBASE, Web of Science, CENTRAL and grey literature between 1960 and 2015. We included studies that reported modification of cardiovascular parameters or incidence/prevalence of cardiovascular outcomes, between a group of subjects exposed to HSCD relative to a non-exposed group. The threshold used to identify HSCD was 391 mg/day. We did not consider studies evaluating exposure to sodium as an active ingredient or those focusing on dialysis solutions or enteral/parenteral nutrition. Study quality was assessed using the EPHPP tool.<h4>Results</h4>A total of eight studies met our inclusion criteria. Four reported results for short-term exposure to HSCD (≤ 7 days) on BP fluctuations. One study reported an elevation of BP (associated sodium intake: 1,656 mg/day). Four studies evaluated a long-term exposure (≥ 2 years or discontinuation of a chronic treatment). Two studies reported iatrogenic risk. For these studies, drug associated sodium intake was high (> 1,500 mg/day) in patients with comorbidities (in particular, diabetes mellitus and hypertension).<h4>Conclusion</h4>Despite numerous study limitations, this systematic review suggests three potential synergistic risk factors for cardiovascular complications after exposure to HSCD: a high sodium intake (≥ 1,500 mg/day), a long duration of exposure, and the presence of comorbidities. Further studies are required to characterize this iatrogenic risk.<h4>Trial registration</h4>PROSPERO CRD42016047086. |
| format | Article |
| id | doaj-art-ebcb86b47b1248128f6d4b403c8f9972 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-ebcb86b47b1248128f6d4b403c8f99722025-08-20T02:20:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018063410.1371/journal.pone.0180634Cardiovascular risk associated with high sodium-containing drugs: A systematic review.Germain PerrinVirginie Korb-SavoldelliAlexandre KarrasNicolas DanchinPierre DurieuxBrigitte Sabatier<h4>Background</h4>Excess dietary sodium is associated with increased blood pressure (BP). Some drugs are associated with high sodium intake (in particular effervescent tablets), but the cardiovascular risk associated with such high sodium-containing drugs (HSCD) is largely underevaluated.<h4>Objectives</h4>To summarize the evidence for a potential cardiovascular risk associated with exposure to HSCD, and to highlight possible risk factors associated with this iatrogenic issue; in general and/or specific populations.<h4>Methods</h4>We conducted a systematic review, by searching electronic databases including MEDLINE, EMBASE, Web of Science, CENTRAL and grey literature between 1960 and 2015. We included studies that reported modification of cardiovascular parameters or incidence/prevalence of cardiovascular outcomes, between a group of subjects exposed to HSCD relative to a non-exposed group. The threshold used to identify HSCD was 391 mg/day. We did not consider studies evaluating exposure to sodium as an active ingredient or those focusing on dialysis solutions or enteral/parenteral nutrition. Study quality was assessed using the EPHPP tool.<h4>Results</h4>A total of eight studies met our inclusion criteria. Four reported results for short-term exposure to HSCD (≤ 7 days) on BP fluctuations. One study reported an elevation of BP (associated sodium intake: 1,656 mg/day). Four studies evaluated a long-term exposure (≥ 2 years or discontinuation of a chronic treatment). Two studies reported iatrogenic risk. For these studies, drug associated sodium intake was high (> 1,500 mg/day) in patients with comorbidities (in particular, diabetes mellitus and hypertension).<h4>Conclusion</h4>Despite numerous study limitations, this systematic review suggests three potential synergistic risk factors for cardiovascular complications after exposure to HSCD: a high sodium intake (≥ 1,500 mg/day), a long duration of exposure, and the presence of comorbidities. Further studies are required to characterize this iatrogenic risk.<h4>Trial registration</h4>PROSPERO CRD42016047086.https://doi.org/10.1371/journal.pone.0180634 |
| spellingShingle | Germain Perrin Virginie Korb-Savoldelli Alexandre Karras Nicolas Danchin Pierre Durieux Brigitte Sabatier Cardiovascular risk associated with high sodium-containing drugs: A systematic review. PLoS ONE |
| title | Cardiovascular risk associated with high sodium-containing drugs: A systematic review. |
| title_full | Cardiovascular risk associated with high sodium-containing drugs: A systematic review. |
| title_fullStr | Cardiovascular risk associated with high sodium-containing drugs: A systematic review. |
| title_full_unstemmed | Cardiovascular risk associated with high sodium-containing drugs: A systematic review. |
| title_short | Cardiovascular risk associated with high sodium-containing drugs: A systematic review. |
| title_sort | cardiovascular risk associated with high sodium containing drugs a systematic review |
| url | https://doi.org/10.1371/journal.pone.0180634 |
| work_keys_str_mv | AT germainperrin cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview AT virginiekorbsavoldelli cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview AT alexandrekarras cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview AT nicolasdanchin cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview AT pierredurieux cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview AT brigittesabatier cardiovascularriskassociatedwithhighsodiumcontainingdrugsasystematicreview |